Cingulate Inc. Warrants
CINGW
About: Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
Employees: 13
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
2.27% less ownership
Funds ownership: 7.86% [Q1] → 5.58% (-2.27%) [Q2]
17% less capital invested
Capital invested by funds: $14.1K [Q1] → $11.7K (-$2.36K) [Q2]
60% less funds holding
Funds holding: 5 [Q1] → 2 (-3) [Q2]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Financial journalist opinion
We haven’t received any recent news articles for CINGW